Better, shorter TB treatment – thanks to SA scientists
Researchers from the universities of Cape Town, Stellenbosch and the Free State were part of the international team that recently discovered that a new combination of drugs was able to kill more TB bacteria more quickly than standard treatment.
The results come after an eight-week trial involving about 200 TB patients from South Africa and Tanzania. Patients either received standard TB treatment – or a novel combination of drugs including the new anti-TB drug PA-824, as well as moxifloxacin and pyrazinamide.
The study is the longest study to date of the new three-drug combination, according to Dr Rodney Dawson, head of research innovation at the University of Cape Town’s Lung Institute.
According to results released yesterday, about 70 percent of patients on the new drug combination showed no sign of TB in sputum samples after two months in comparison to only 50 percent of those patients on standard TB treatment.
This new drug combination could potentially shorten standard TB treatment from the current six months to just four, Dawson told Health-e News Service.
With about 20 percent of the study sample comprised of HIV-positive patients, the study showed that the new treatment combination could safely be taken in conjunction with antiretrovirals.
In South Africa, about 60 percent of TB patients are co-infected with HIV
[quote float=”right”]The new combination could work for TB patients as well as up to 30 percent of MDR-TB patients
Importantly, the study may also pave the way for shorter, easier treatment for multidrug-resistant (MDR-TB) patients, which comprised about 10 percent of the study sample.
Researchers found that MDR-TB patients responded similarly well to the new combination. This could mean the three-drug combination could reduce MDR-TB treatment by about 16 months, cut the number of pills by 97 percent and greatly reduce costs, according to TB Alliance.
However, Dawson cautions that these results will only apply to the up to 30 percent of MDR-TB patients whose illnesses will respond to pyrazinamide.
MDR-TB is resistant to both of the most commonly used anti-TB drugs, rifampicin and isoniazid. In 2012, South Africa diagnosed more than 15000 MDR-TB cases, according to the World Health Organisation.
A longer, follow-up study on the novel drug trio is set to start in 2015. The 1500-person study will be conducted in 10 countries – including South Africa, China and Zambia – and should produce results by 2018. – Health-e News Service.
Author
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Better, shorter TB treatment – thanks to SA scientists
by lauralopez, Health-e News
July 22, 2014